Morgan Stanley Reiterates Overweight on Intra-Cellular Therapies, Maintains $80 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has reiterated an Overweight rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a price target of $80.
August 04, 2023 | 5:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has reiterated an Overweight rating on Intra-Cellular Therapies, maintaining a price target of $80.
The reiteration of an Overweight rating by a major financial institution like Morgan Stanley is a positive signal for Intra-Cellular Therapies. The maintained price target of $80 indicates that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100